Navigation Links
Lilly Declares Third-Quarter Dividend
Date:6/20/2008

INDIANAPOLIS, June 20 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first and second quarters and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable September 10, 2008, to shareholders of record at the close of business on August 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... leading private owners, developers and operators of commercial real estate proudly announced that ... 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ annual ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is ... and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative ... to attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... East Providence, Rhode Island (PRWEB) , ... May ... ... website was launched in April 2016. SS&A teamed up with one of the ... website. This legal information portal contains informative legal articles related to the law ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: